<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759315</url>
  </required_header>
  <id_info>
    <org_study_id>3682-035</org_study_id>
    <secondary_id>MK-3682-035</secondary_id>
    <nct_id>NCT02759315</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)</brief_title>
  <official_title>A Phase II, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682 + MK-8408 in Subjects With Chronic HCV Genotype 1, 2, 3, 4, 5 or 6 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, multi-center trial to evaluate the novel 2-drug regimen of
      uprifosbuvir (MK-3682) 450 mg and ruzasvir (MK-8408) 60 mg in participants with chronic
      hepatitis C virus (HCV) genotype (GT)1, GT2, GT3, GT4, GT5, or GT6 infection. The impact of
      the study treatment regimen on the percentage of participants with undetectable HCV
      ribonucleic acid [RNA] 12 weeks after completing study treatment (SVR12) will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated based on review of Phase 2 efficacy data
  </why_stopped>
  <start_date type="Actual">May 3, 2016</start_date>
  <completion_date type="Actual">November 16, 2017</completion_date>
  <primary_completion_date type="Actual">July 27, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)</measure>
    <time_frame>Week 24 (12 weeks after completing study therapy)</time_frame>
    <description>The percentage of participants in each arm achieving SVR12 was determined. SVR12 was defined as HCV ribonucleic acid (RNA) levels in plasma &lt; lower limit of quantification (LLOQ) 12 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With ≥1 Adverse Events (AEs)</measure>
    <time_frame>Up to Week 14 (up to 2 weeks after completing study therapy)</time_frame>
    <description>The percentage of participants experiencing an AE during the treatment period and first 2 weeks of follow-up was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Withdrawing From Study Therapy Due to an AE</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>The percentage of participants discontinuing from study therapy during the treatment period was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With ≥1 Events of Clinical Interest (ECIs)</measure>
    <time_frame>Up to Week 14 (up to 2 weeks after completing study therapy)</time_frame>
    <description>The percentage of participants with ECIs was determined. ECIs were defined as the following: 1) an overdose of study drug; 2) first instance of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;500 IU/L; 3) first instance of ALT or AST &gt;3x nadir and &gt;3x upper limit of normal (ULN); 4) first instance of estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m^2; or 4) first instance of serum creatinine &gt;1.3x ULN and elevated from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24)</measure>
    <time_frame>Week 36 (24 weeks after completing study therapy)</time_frame>
    <description>The percentage of participants in each arm achieving SVR24 was determined. SVR24 was defined as HCV RNA levels in plasma &lt; LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL. For SVR24, participants with GT1 infection were separated into GT1a or GT1b infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Failure (VF)</measure>
    <time_frame>12 weeks after the end of all study therapy (24 weeks)</time_frame>
    <description>The percentage of participants in each arm experiencing VF was determined. VF was defined as: 1) non-response (HCV RNA detected at end of treatment without HCV RNA &lt; LLOQ while on treatment); 2) rebound (&gt;1 log 10 IU/mL increase in HCV RNA from nadir while on treatment); 3) virologic breakthrough (HCV RNA ≥LLOQ after being &lt;LLOQ on treatment); or 4) relapse (HCV RNA ≥LLOQ after end of all study therapy after being undetectable at end of treatment); virologic failure could occur either on-treatment or relapse post-treatment. For VF, participants with GT1 infection were separated into GT1a or GT1b infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Baseline Resistance-Associated Substitutions (RAS) Achieving SVR12</measure>
    <time_frame>12 weeks after the end of all study therapy (24 weeks)</time_frame>
    <description>The percentage of participants in each arm with baseline RAS achieving SVR12 was determined. Analysis of RAS in NS5A or NS5B at baseline was determined. SVR12 was defined as HCV RNA levels in plasma &lt; LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT1 Arm is sub-divided into GT1a and GT1b Arms. GT1a Arm will enroll approximately 35 participants including up to 10 participants who are compensated cirrhotics and GT1b Arm will enroll approximately 15 participants including up to 5 participants who are compensated cirrhotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT2 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT3 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT4 Arm of the study will enroll approximately 50 participants including up to 15 participants who are compensated cirrhotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT5: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT5 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an oral dose of 450 mg uprifosbuvir (3 x 150 mg tablets) and 60 mg ruzasvir (6 x 10 mg capsules) following an overnight fast and at least one hour before a meal, once a day, for 12 weeks. The GT6 Arm of the study will enroll approximately 25 participants including both non- cirrhotics and compensated cirrhotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uprifosbuvir 450 mg</intervention_name>
    <description>450 mg administered as 3 x 150 mg oral tablets</description>
    <arm_group_label>GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_label>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_label>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_label>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_label>GT5: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_label>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <other_name>MK-3682</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruzasvir 60 mg</intervention_name>
    <description>60 mg administered as 6 x 10 mg oral capsules</description>
    <arm_group_label>GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_label>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_label>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_label>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_label>GT5: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <arm_group_label>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</arm_group_label>
    <other_name>MK-8408</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has hepatitis C virus (HCV) ribonucleic acid (RNA) at the time of screening

          -  Has documented chronic HCV genotype (GT)1, GT2, GT3, GT4, GT5, or GT6 with no evidence
             of non-typeable or mixed GT infection

          -  Is otherwise healthy as determined by the medical history, physical examination,
             electrocardiogram (ECG), and clinical laboratory measurements performed at the time of
             screening

          -  Has absence of cirrhosis or has compensated cirrhosis

          -  Is HCV treatment-naïve or has experienced virologic failure after completing a prior
             interferon-containing regimen

          -  Is of non-childbearing potential or agrees to avoid becoming pregnant or impregnating
             a partner beginning at least 2 weeks prior to administration of the initial dose of
             study drug and for 14 days after the last dose of study drug

          -  For human immunodeficiency virus (HIV) co-infected participants: is not currently on
             antiretroviral therapy (ART) and has no plans to initiate ART treatment while
             participating in this study Or has well-controlled HIV on ART

        Exclusion Criteria:

          -  Is mentally or legally incapacitated, has significant emotional problems (at screening
             or expected during the study) or has a history of a clinically significant psychiatric
             disorder that would interfere with the study procedures.

          -  Has evidence of decompensated liver disease manifested by the presence of or history
             of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other
             signs or symptoms of advanced liver disease

          -  Is Child-Pugh Class B or C or has a Pugh-Turcotte (CPT) score &gt;6 if cirrhotic

          -  Is co-infected with Hepatitis B Virus

          -  Has a history of opportunistic infection in the preceding 6 months prior to screening
             if co-infected with HIV

          -  Has a history of malignancy ≤5 years prior to study start (except for adequately
             treated basal cell or squamous cell skin cancer or in situ cervical cancer or
             carcinoma in situ) or is under evaluation for other active or suspected malignancy

          -  Has cirrhosis and liver imaging within 6 months prior to study start showing evidence
             of hepatocellular carcinoma (HCC) or is under evaluation for HCC

          -  Is taking any medications or herbal supplements restricted by the study entry criteria
             in the period from ≤2 weeks prior to study start through 2 weeks after the last dose
             of study drug

          -  Has clinically-relevant drug or alcohol abuse within 12 months of study start

          -  Has participated in any clinical study of an investigational product within 30 days
             prior to the first dose of study drug

          -  Is female and is pregnant or breastfeeding, or expecting to conceive or donate eggs
             from at least 2 weeks prior to study start and 14 days after the last dose of study
             drug

          -  Is male and is expecting to donate sperm from at least 2 weeks prior to Day 1 until 14
             days after the last dose of study drug

          -  Has or has had any of the following: organ transplants (including hematopoietic stem
             cell transplants) other than cornea and hair; poor venous access; history of gastric
             surgery; or history of malabsorption disorders

          -  Has any cardiac abnormalities/dysfunction including but not limited to: unstable
             angina; unstable congestive heart failure; or unstable arrhythmia

          -  Has a history of a medical/surgical condition that resulted in hospitalization within
             3 months prior to study start, other than for minor elective procedures

          -  Has any medical condition requiring, or likely to require, chronic systemic
             administration of corticosteroids, tumor necrosis factor (TNF) antagonists, or other
             immunosuppressant drugs during the study

          -  Has evidence of history of chronic hepatitis not caused by HCV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Lawitz E, Poordad F, Anderson LJ, Vesay M, Kelly MM, Liu H, Gao W, Fernsler D, Asante-Appiah E, Robertson MN, Hanna GJ, Barr E, Butterton J, Kowdley KV, Hassanein T, Sahota A, Gordon SC, Yeh WW. Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. J Viral Hepat. 2019 Jun;26(6):675-684. doi: 10.1111/jvh.13079. Epub 2019 Mar 12.</citation>
    <PMID>30739366</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <results_first_submitted>July 10, 2018</results_first_submitted>
  <results_first_submitted_qc>July 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2018</results_first_posted>
  <last_update_submitted>June 11, 2019</last_update_submitted>
  <last_update_submitted_qc>June 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uprifosbuvir</mesh_term>
    <mesh_term>Ruzasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02759315/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adult participants with hepatitis C virus (HCV) genotype (GT) 1, 2, 3, 4, or 6 infection were enrolled at 5 study centers in the United States. Participants with HCV GT5 infection were initially intended for inclusion but none were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT1 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="P2">
          <title>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT2 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="P3">
          <title>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT3 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="P4">
          <title>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT4 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="P5">
          <title>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT6 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="39"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated prior to completion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT1 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="B2">
          <title>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT2 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="B3">
          <title>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT3 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="B4">
          <title>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT4 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="B5">
          <title>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT6 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.8" spread="10.7"/>
                    <measurement group_id="B2" value="57.2" spread="6.8"/>
                    <measurement group_id="B3" value="48.7" spread="10.3"/>
                    <measurement group_id="B4" value="56.5" spread="8.5"/>
                    <measurement group_id="B5" value="61.3" spread="1.5"/>
                    <measurement group_id="B6" value="51.9" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)</title>
        <description>The percentage of participants in each arm achieving SVR12 was determined. SVR12 was defined as HCV ribonucleic acid (RNA) levels in plasma &lt; lower limit of quantification (LLOQ) 12 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.</description>
        <time_frame>Week 24 (12 weeks after completing study therapy)</time_frame>
        <population>All participants who received ≥1 dose of study treatment, have data available, who do not have protocol deviations that could substantially affect the results of the endpoint, and who did not discontinue from the study for non-treatment-related reasons, are included.</population>
        <group_list>
          <group group_id="O1">
            <title>GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT1 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O2">
            <title>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT2 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O3">
            <title>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT3 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O4">
            <title>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT4 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O5">
            <title>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT6 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)</title>
          <description>The percentage of participants in each arm achieving SVR12 was determined. SVR12 was defined as HCV ribonucleic acid (RNA) levels in plasma &lt; lower limit of quantification (LLOQ) 12 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.</description>
          <population>All participants who received ≥1 dose of study treatment, have data available, who do not have protocol deviations that could substantially affect the results of the endpoint, and who did not discontinue from the study for non-treatment-related reasons, are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1" lower_limit="89.9" upper_limit="99.6"/>
                    <measurement group_id="O2" value="100.0" lower_limit="87.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="76.9" lower_limit="60.7" upper_limit="88.9"/>
                    <measurement group_id="O4" value="90.0" lower_limit="68.3" upper_limit="98.8"/>
                    <measurement group_id="O5" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With ≥1 Adverse Events (AEs)</title>
        <description>The percentage of participants experiencing an AE during the treatment period and first 2 weeks of follow-up was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
        <time_frame>Up to Week 14 (up to 2 weeks after completing study therapy)</time_frame>
        <population>All participants who received ≥1 dose of study drug are included.</population>
        <group_list>
          <group group_id="O1">
            <title>GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT1 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O2">
            <title>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT2 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O3">
            <title>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT3 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O4">
            <title>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT4 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O5">
            <title>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT6 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥1 Adverse Events (AEs)</title>
          <description>The percentage of participants experiencing an AE during the treatment period and first 2 weeks of follow-up was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
          <population>All participants who received ≥1 dose of study drug are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="44.8"/>
                    <measurement group_id="O3" value="43.6"/>
                    <measurement group_id="O4" value="55.0"/>
                    <measurement group_id="O5" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Withdrawing From Study Therapy Due to an AE</title>
        <description>The percentage of participants discontinuing from study therapy during the treatment period was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
        <time_frame>Up to Week 12</time_frame>
        <population>All participants who received ≥1 dose of study drug are included.</population>
        <group_list>
          <group group_id="O1">
            <title>GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT1 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O2">
            <title>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT2 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O3">
            <title>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT3 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O4">
            <title>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT4 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O5">
            <title>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT6 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Withdrawing From Study Therapy Due to an AE</title>
          <description>The percentage of participants discontinuing from study therapy during the treatment period was determined. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
          <population>All participants who received ≥1 dose of study drug are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="5.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24)</title>
        <description>The percentage of participants in each arm achieving SVR24 was determined. SVR24 was defined as HCV RNA levels in plasma &lt; LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL. For SVR24, participants with GT1 infection were separated into GT1a or GT1b infection.</description>
        <time_frame>Week 36 (24 weeks after completing study therapy)</time_frame>
        <population>All participants who received ≥1 dose of study treatment, have data available, who do not have protocol deviations that could substantially affect the results of the endpoint, and who did not discontinue from the study for non-treatment-related reasons, are included.</population>
        <group_list>
          <group group_id="O1">
            <title>GT1a: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT1a infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O2">
            <title>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT2 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O3">
            <title>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT3 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O4">
            <title>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT4 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O5">
            <title>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT6 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O6">
            <title>GT1b: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT1b infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completing Study Therapy (SVR24)</title>
          <description>The percentage of participants in each arm achieving SVR24 was determined. SVR24 was defined as HCV RNA levels in plasma &lt; LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL. For SVR24, participants with GT1 infection were separated into GT1a or GT1b infection.</description>
          <population>All participants who received ≥1 dose of study treatment, have data available, who do not have protocol deviations that could substantially affect the results of the endpoint, and who did not discontinue from the study for non-treatment-related reasons, are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.2"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="75.0"/>
                    <measurement group_id="O4" value="90.0"/>
                    <measurement group_id="O5" value="66.7"/>
                    <measurement group_id="O6" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Failure (VF)</title>
        <description>The percentage of participants in each arm experiencing VF was determined. VF was defined as: 1) non-response (HCV RNA detected at end of treatment without HCV RNA &lt; LLOQ while on treatment); 2) rebound (&gt;1 log 10 IU/mL increase in HCV RNA from nadir while on treatment); 3) virologic breakthrough (HCV RNA ≥LLOQ after being &lt;LLOQ on treatment); or 4) relapse (HCV RNA ≥LLOQ after end of all study therapy after being undetectable at end of treatment); virologic failure could occur either on-treatment or relapse post-treatment. For VF, participants with GT1 infection were separated into GT1a or GT1b infection</description>
        <time_frame>12 weeks after the end of all study therapy (24 weeks)</time_frame>
        <population>All participants who received ≥1 dose of study treatment, have data available, who do not have protocol deviations that could substantially affect the results of the endpoint, and who did not discontinue from the study for non-treatment-related reasons, are included.</population>
        <group_list>
          <group group_id="O1">
            <title>GT1a: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT1a infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O2">
            <title>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT2 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O3">
            <title>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT3 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O4">
            <title>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT4 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O5">
            <title>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT6 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O6">
            <title>GT1b: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT1b infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Failure (VF)</title>
          <description>The percentage of participants in each arm experiencing VF was determined. VF was defined as: 1) non-response (HCV RNA detected at end of treatment without HCV RNA &lt; LLOQ while on treatment); 2) rebound (&gt;1 log 10 IU/mL increase in HCV RNA from nadir while on treatment); 3) virologic breakthrough (HCV RNA ≥LLOQ after being &lt;LLOQ on treatment); or 4) relapse (HCV RNA ≥LLOQ after end of all study therapy after being undetectable at end of treatment); virologic failure could occur either on-treatment or relapse post-treatment. For VF, participants with GT1 infection were separated into GT1a or GT1b infection</description>
          <population>All participants who received ≥1 dose of study treatment, have data available, who do not have protocol deviations that could substantially affect the results of the endpoint, and who did not discontinue from the study for non-treatment-related reasons, are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="23.1"/>
                    <measurement group_id="O4" value="5.0"/>
                    <measurement group_id="O5" value="33.3"/>
                    <measurement group_id="O6" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Baseline Resistance-Associated Substitutions (RAS) Achieving SVR12</title>
        <description>The percentage of participants in each arm with baseline RAS achieving SVR12 was determined. Analysis of RAS in NS5A or NS5B at baseline was determined. SVR12 was defined as HCV RNA levels in plasma &lt; LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.</description>
        <time_frame>12 weeks after the end of all study therapy (24 weeks)</time_frame>
        <population>All participants who received ≥1 dose of study treatment, and who do not have protocol deviations that could substantially affect the results of the endpoint, and who did not discontinue from the study for non-treatment-related reasons, and who had baseline sequencing data available, are included.</population>
        <group_list>
          <group group_id="O1">
            <title>GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT1 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O2">
            <title>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT2 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O3">
            <title>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT3 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O4">
            <title>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT4 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O5">
            <title>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT6 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Baseline Resistance-Associated Substitutions (RAS) Achieving SVR12</title>
          <description>The percentage of participants in each arm with baseline RAS achieving SVR12 was determined. Analysis of RAS in NS5A or NS5B at baseline was determined. SVR12 was defined as HCV RNA levels in plasma &lt; LLOQ 24 weeks after completing study treatment. Plasma levels of HCV RNA were measured with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL.</description>
          <population>All participants who received ≥1 dose of study treatment, and who do not have protocol deviations that could substantially affect the results of the endpoint, and who did not discontinue from the study for non-treatment-related reasons, and who had baseline sequencing data available, are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1"/>
                    <measurement group_id="O2" value="100.0"/>
                    <measurement group_id="O3" value="97.4"/>
                    <measurement group_id="O4" value="94.7"/>
                    <measurement group_id="O5" value="66.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With ≥1 Events of Clinical Interest (ECIs)</title>
        <description>The percentage of participants with ECIs was determined. ECIs were defined as the following: 1) an overdose of study drug; 2) first instance of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;500 IU/L; 3) first instance of ALT or AST &gt;3x nadir and &gt;3x upper limit of normal (ULN); 4) first instance of estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m^2; or 4) first instance of serum creatinine &gt;1.3x ULN and elevated from baseline.</description>
        <time_frame>Up to Week 14 (up to 2 weeks after completing study therapy)</time_frame>
        <population>All participants who received ≥1 dose of study drug are included.</population>
        <group_list>
          <group group_id="O1">
            <title>GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT1 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O2">
            <title>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT2 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O3">
            <title>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT3 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O4">
            <title>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT4 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
          <group group_id="O5">
            <title>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
            <description>Participants with HCV GT6 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With ≥1 Events of Clinical Interest (ECIs)</title>
          <description>The percentage of participants with ECIs was determined. ECIs were defined as the following: 1) an overdose of study drug; 2) first instance of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;500 IU/L; 3) first instance of ALT or AST &gt;3x nadir and &gt;3x upper limit of normal (ULN); 4) first instance of estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m^2; or 4) first instance of serum creatinine &gt;1.3x ULN and elevated from baseline.</description>
          <population>All participants who received ≥1 dose of study drug are included.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-overdose ECI</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8"/>
                    <measurement group_id="O3" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 36 weeks (up to 24 weeks after completing study treatment)</time_frame>
      <desc>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. All participants who received ≥1 dose of study drug are included.</desc>
      <group_list>
        <group group_id="E1">
          <title>GT1: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT1 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="E2">
          <title>GT2: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT2 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="E3">
          <title>GT3: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT3 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="E4">
          <title>GT4: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT4 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
        <group group_id="E5">
          <title>GT6: Uprifosbuvir 450 mg + Ruzasvir 60 mg</title>
          <description>Participants with HCV GT6 infection took uprifosbuvir 450 mg ruzasvir 60 mg once daily for 12 weeks. Study drug was taken after an overnight fast and at least 1 hour before a meal.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oesophagitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

